title: Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers.
abstract: This investigation was carried out to evaluate the bioavailability of a new suspension formulation of cefixime (100 mg/5 ml), Winex, relative to the reference product, Suprax (100 mg/5 ml) suspension. The bio-availability study was carried out in 24 healthy male volunteers who received a single oral dose (200 mg) of the test (A) and the reference (B) products on 2 treatment days after an overnight fast of at least 10 hours. The treatment periods were separated by a one-week washout period. A randomized, balanced two-way crossover design was used. After dosing, serial blood samples were collected over a period of 16 hours. Plasma concentrations of cefixime were analyzed using a sensitive high-performance liquid chromatographic assay. The pharmacokinetic parameters for cefixime were determined using standard non-compartmental method. The parameters AUC(0-t), AUC(0-infinity), Cmax, Kel, t1/2 and Cmax/AUC(0-infinity) were analyzed statistically using raw and log-transformed data. The time to maximum concentration (tmax) was analyzed using raw data. The parametric 90% confidence intervals of the mean values of the pnfinity harmacokinetic parameters: AUC(0-t), AUC(0-infinity) Cmax, and Cmax/AUC(0-infinity) were within the range 80 - 125% which is acceptable for bioequivalence (using log-transformed data). The calculated 90% confidence intervals based on the ANOVA analysis for the mean test/reference ratios of AUC(0-t), AUC(0-infinity), Cmax, and Cmax/AUC(0-infinity) were 88.93 - 107.10%, 89.09 - 107.11%, 89.63 - 108.58% and 96.85 - 105.29%, respectively. The test formulation was found bioequivalent to the reference formulation with regard to AUC(0-t), AUC(0-infinity), and Cmax using the Schuirmann's two one-sided t-tests. Therefore, the two formulations were considered to be bioequivalent.
authors.affiliation: Department of Clinical Pharmacy, College of Pharmacy, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia. yasiri07@ksu.edu.sa
authors.forename: Y A
authors.initials: YA
authors.lastname: Asiri
authors.forename: M S
authors.initials: MS
authors.lastname: Al-Said
authors.forename: K I
authors.initials: KI
authors.lastname: Al-Khamis
authors.forename: E M
authors.initials: EM
authors.lastname: Niazy
authors.forename: Y M
authors.initials: YM
authors.lastname: El-Sayed
authors.forename: K A
authors.initials: KA
authors.lastname: Al-Rashood
authors.forename: M J
authors.initials: MJ
authors.lastname: Al-Yamani
authors.forename: I A
authors.initials: IA
authors.lastname: Alsarra
authors.forename: S A
authors.initials: SA
authors.lastname: Al-Balla
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D020682:Cefixime / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008297:Male; D013535:Suspensions; D013810:Therapeutic Equivalency
chemical_list: D000900:Anti-Bacterial Agents; D013535:Suspensions; D020682:Cefixime